Molecular Endocrinology, Vol 7, 114-130, Copyright © 1993 by Endocrine Society

ARTICLES

Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor

S Kosugi, T Ban and LD Kohn
Laboratory of Biochemistry and Metabolism, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.

Using mutants of the N-terminal region (residues 30-76) of the rat TSH receptor (TSHR), which substitute corresponding segments of rat gonadotropin receptors or hydrophilic (serine) and hydrophobic (alanine) amino acids as appropriate, we show that residues 30-33, 34- 37, 42-45, 52-56, and 58-61, in addition to threonine-40, are determinants for the interaction of thyroid-stimulating autoantibodies (stimulating TSHRAbs) with the TSHR. The most important, residues 34- 37, 42-45, and 52-56, whose mutants lose stimulating TSHRAb activity with at least 11 of 12 (> 90%) of the Graves' immunoglobulins G tested, are, like threonine-40, in regions of the TSHR that are nonhomologous with gonadotropin receptors. These data establish at least in part, therefore, the basis for the thyroid-specific effects of stimulating TSHRAbs. In no case do the same mutants lose their reactivity with TSH or blocking-type TSHR autoantibodies (blocking TSHRAbs) from hypothyroid patients with idiopathic myxedema. Since the latter have been shown to interact with high affinity TSH-binding sites on the C- terminal portion of the external domain of the TSHR, stimulating TSHRAbs and blocking TSHRAbs react with different receptor determinants, which can be presumed to have different roles in receptor function. This can explain the hyper- or hypothyroidism of different thyroid autoimmune diseases with receptor antibodies. Residues 30-33, 42-45, and threonine-40 appear to be related to the agonist action of TSH, since in each case mutation results in low affinity TSH binding, but normal TSH-increased cAMP activity, similar, for example, to a beta- adrenergic agonist. Using a receptor antibody to identify different receptor forms in the membrane, we can also identify determinants in this N-terminal region (residues 30-76) whose mutation results in a loss of all activities without apparently altering receptor synthesis, processing, or integration within the bilayer. These are residues 38 and 39, cysteine-41, residues 46-51, leucine-57, threonine-62, and, within residues 66-76, serine-69, alanine-71, phenylalanine-72, serine- 74, leucine-75, and proline-76. We suggest that these residues are at the very least important in the conformational array of receptor determinants necessary for interactions with TSH and stimulating TSHRAbs.

This article has been cited by other articles:

				G. D. Chazenbalk, F. Latrofa, S. M. McLachlan, and B. Rapoport Thyroid Stimulation Does Not Require Antibodies with Identical Epitopes But Does Involve Recognition of a Critical Conformation at the N Terminus of the Thyrotropin Receptor A-Subunit J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1788 - 1793. [Abstract] [Full Text] [PDF]

				A. W. C. Kung, K. S. Lau, and L. D. Kohn Epitope Mapping of TSH Receptor-Blocking Antibodies in Graves' Disease That Appear during Pregnancy J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3647 - 3653. [Abstract] [Full Text] [PDF]

				A. Di Cerbo, R. Di Paola, C. Menzaghi, V. De Filippis, K. Tahara, D. Corda, and L. D. Kohn Graves' Immunoglobulins Activate Phospholipase A2 by Recognizing Specific Epitopes on Thyrotropin Receptor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3283 - 3292. [Abstract] [Full Text]

				T. Akamizu, K. Moriyama, M. Miura, M. Saijo, F. Matsuda, and K. Nakao Characterization of Recombinant Monoclonal Antithyrotropin Receptor Antibodies (TSHRAbs) Derived from Lymphocytes of Patients with Graves' Disease: Epitope and Binding Study of Two Stimulatory TSHRAbs Endocrinology, April 1, 1999; 140(4): 1594 - 1601. [Abstract] [Full Text]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				S. Kikuoka, N. Shimojo, K.-I. Yamaguchi, Y. Watanabe, A. Hoshioka, A. Hirai, Y. Saito, K. Tahara, L. D. Kohn, N. Maruyama, et al. The Formation of Thyrotropin Receptor (TSHR) Antibodies in a Graves' Animal Model Requires the N-Terminal Segment of the TSHR Extracellular Domain Endocrinology, April 1, 1998; 139(4): 1891 - 1898. [Abstract] [Full Text] [PDF]

				S. Costagliola, P. Rodien, M.-C. Many, M. Ludgate, and G. Vassart Genetic Immunization Against the Human Thyrotropin Receptor Causes Thyroiditis and Allows Production of Monoclonal Antibodies Recognizing the Native Receptor J. Immunol., February 1, 1998; 160(3): 1458 - 1465. [Abstract] [Full Text] [PDF]

				L. D. Kohn, K. Suzuki, W. H. Hoffman, D. Tombaccini, C. Marcocci, N. Shimojo, Y. Watanabe, N. Amino, B. Y. Cho, Y. Kohno, et al. Characterization of Monoclonal Thyroid-Stimulating and Thyrotropin Binding-Inhibiting Autoantibodies from a Hashimoto's Patient Whose Children Had Intrauterine and Neonatal Thyroid Disease J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3998 - 4009. [Abstract] [Full Text] [PDF]

				S. A. Patibandla, J. S. Dallas, G. S. Seetharamaiah, K. Tahara, L. D. Kohn, and B. S. Prabhakar Flow Cytometric Analyses of Antibody Binding to Chinese Hamster Ovary Cells Expressing Human Thyrotropin Receptor J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1885 - 1893. [Abstract] [Full Text] [PDF]

				W. B. Kim, H. K. Chung, H. K. Lee, L. D. Kohn, K. Tahara, and B. Y. Cho Changes in Epitopes for Thyroid-Stimulating Antibodies in Graves' Disease Sera During Treatment of Hyperthyroidism: Therapeutic Implications J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1953 - 1959. [Abstract] [Full Text] [PDF]

				B. W. O'Malley Jr and F. D. Ledley Somatic Gene Therapy in Otolaryngology--Head and Neck Surgery Arch Otolaryngol Head Neck Surg, November 1, 1993; 119(11): 1191 - 1197. [Abstract] [PDF]

				C.-R. Chen, K. Tanaka, G. D. Chazenbalk, S. M. McLachlan, and B. Rapoport A Full Biological Response to Autoantibodies in Graves' Disease Requires a Disulfide-bonded Loop in the Thyrotropin Receptor N Terminus Homologous to a Laminin Epidermal Growth Factor-like Domain J. Biol. Chem., April 27, 2001; 276(18): 14767 - 14772. [Abstract] [Full Text] [PDF]